CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright

CG Oncology (NASDAQ:CGON)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 106.78% from the company’s current price.

CGON has been the topic of a number of other research reports. The Goldman Sachs Group initiated coverage on shares of CG Oncology in a report on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price target on the stock. Morgan Stanley began coverage on shares of CG Oncology in a report on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of CG Oncology in a report on Thursday.

CG Oncology Stock Performance

Shares of CGON stock opened at $36.27 on Monday. The company’s 50 day simple moving average is $39.63. CG Oncology has a 12 month low of $28.55 and a 12 month high of $50.23.

Institutional Investors Weigh In On CG Oncology

An institutional investor recently bought a new position in CG Oncology stock. Capstone Investment Advisors LLC purchased a new position in CG Oncology, Inc. (NASDAQ:CGON) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,354 shares of the company’s stock, valued at approximately $806,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.